This is Not the End – A Survivor’s Story
A story about a cancer survivor recently appeared in the Washington Post: “This is not the end; Using immunotherapy and a genetic glitch to give cancer patients hope”. The story is about a young [...]
The LRG Stresses Management of Side Effects
We are in the midst of one of the most exciting times in history to be involved in cancer research. Over 60 anti-cancer drugs have gained FDA-approval in the last 10 years, and that [...]
Side Effects Management Vital to the Quality of Life
In a recent article in Cure Today, LRG Marketing Director, Erin Kristoff, details the importance of side effects management and the role the LRG plays in helping to extend survival and to improve the [...]
Informative Webcast Sheds Light on Mutational Analysis
Dr. Chris Corless In August, the LRG Webcast Series presented “Mutational Analysis of GISTs: How, When and Why.” Dr. Christopher Corless of Oregon Health and Science University (OHSU) presented the hour- long [...]
First GDOL Chicago hits a homerun!
Our first Chicago GIST Day of Learning (GDOL) was a huge success! Over 50 GISTers and their families gathered for a great day of learning, and sharing experiences. It was wonderful to get to meet so many new people and reconnect with old friends.
PDGFRA Mutations: It’s time to consider mutational status for resistant GIST patients
January 6th, 2011 - By Jerry Call, LRG Science CoordinatorThe first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled to open in [...]